Crizotinib may be effective again after chemo

Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. This case is a proof of concept that re-challenging with crizotinib after intervening chemotherapy is feasible in ROS1-rearranged NSCLC with acquired resistance. Read full article here.

NICE in UK refuses to recommend crizotinib for ROS1+ NSCLC

Last week the National Institute for Health and Care Excellence (NICE) decided not to recommend Xalkori for the treatment of ROS-positive non-small cell lung cancer in the United Kingdom. More information here: NICE Appraisal Consultation Document NICE shoots down Pfizer’s Xalkori in ROS1-positive patients, inviting a CDF proposal instead (from Fierce Biotech)